Miriam Bujny

Miriam Bujny has a strong background in scientific research and development. Miriam is currently serving as the Chief Development Officer at Sapreme Technologies BV since October 2020. Prior to that, they held various roles at ProQR Therapeutics from 2016 to 2020, including Senior Director R&D - Translational Science and Director Biomarkers. In these positions, they were responsible for developing and overseeing the translational strategy for biomarker/outcome measures, managing relationships with external partners and vendors, and providing scientific leadership.

Miriam also worked at The Janssen Pharmaceutical Companies of Johnson & Johnson from 2012 to 2016 as a Principal Scientist and Senior Scientist. During this time, they led a team of scientists and staff, conducted biofluid protein marker assays for neurodegenerative diseases, and explored novel assay concepts.

Miriam started their career at Crucell in 2010 as a Scientist, where they led a team in performing anti-viral screening and development, as well as characterization of antivirals/monoclonal antibodies. Miriam also worked as a Postdoctoral Fellow at Harvard University from 2007 to 2010, investigating influenza A virus assembly and characterizing cellular factors important in influenza entry.

In addition, they worked briefly as an Auditor at Harvard Business School in 2008 and as a Graduate Student (Intern) at PerkinElmer LAS from 2003 to 2006.

Miriam Bujny obtained their BTA degree from Rheinische Akademie Köln in 1998, working as a Research Assistant in Biology. Miriam then pursued their higher education at Ruhr University Bochum from 1998 to 2003, earning a Diploma (MSc) in Biochemistry. Following that, they attended the University of Bristol from 2003 to 2006 and received their PhD in Biochemistry/Cell Biology.